Estaba claro!
A ver que dice zocatira ...
Ya fue un súper red flag el delay en el data Read out
Acasti Pharma's pain is Amarin's gain, up 12% premarket
• Acasti Pharma (NASDAQ:
ACST) craters 60% premarket on modest volume (thus far) in response to
unsuccessful results from a Phase 3 clinical trial,
TRILOGY 1, evaluating lead candidate CaPre (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia.
• CaPre failed to sufficiently separate from placebo in terms of reducing triglyceride levels. Specifically, the median reduction in the CaPre arm was 30.5% versus 27.5% in the control arm at week 12. The mean reductions in patients on background statin therapy were 42.2% and 31.5%, respectively, at week 12.
• At week 26, the end of the study, the median reduction of triglycerides in CaPre group was 36.7% compared to 28.0% in the placebo group.
• None of the differences reached statistical significance.
• Data on all secondary and exploratory endpoints should be available by quarter-end.
• Topline results from a second Phase 3,
TRILOGY 2, should be reported in mid-February.
• Amarin (NASDAQ:
AMRN), whose Vascepa (icosapent ethyl) was approved in the U.S. in July 2012 for severe hypertriglyceridemia, is up 12% premarket on light volume.